# Taysha Gene Therapies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/taysha-gene-therapies

- Industry: Biotechnology
- Headquarters: Dallas, US
- Website: www.tayshagtx.com
- Total disclosed funding: $114M
- Latest round: Series B (Jul 2, 2020)
- Investors on record: 13

## About

Taysha Gene Therapies, Inc. is a Dallas-based biotechnology company specializing in gene therapies aimed at treating monogenic diseases of the central nervous system (CNS).Founded in 2020 and headquartered in Dallas, US, Taysha Gene Therapies, Inc. focuses on developing innovative gene therapies. The company has undergone strategic efforts to secure partnerships within the healthcare sector. Sean Nolan serves as CEO. They successfully raised USD 40.00 mn in VENTURE DEBT funding in September 2020, contributing to a total amount raised of USD 150.00 mn through seven deals.Taysha Gene Therapies is dedicated to discovering and commercializing gene therapies for monogenic diseases affecting the CNS. Their leading product, TSHA-102, targets Rett syndrome, a genetic disorder leading to severe intellectual disability in females. The company utilizes advanced gene therapy techniques to address genetic mutations and enhance life quality for patients. Taysha's customer base includes patients, healthcare providers, and organizations in the rare disease community, with a primary focus on the US market and plans for future expansion into Europe and Asia.In 2024, Taysha Gene Therapies reported revenue of USD 8.33 mn, with an EBITDA of USD -90.21 mn. Revenue generation is achieved through partnerships with pharmaceutical companies and research institutions, driven by clinical trial agreements and future sales from TSHA-102 upon FDA approval.Taysha Gene Therapies plans to launch new products, including the TSHA-102 gene therapy for Rett syndrome. With the recent funding of USD 40.00 mn raised in September 2020, the company aims to support further product development and expand its market reach into Europe and Asia by 2025. The company also continues to explore opportunities for additional funding to bolster its growth strategy.

## Funding rounds

- Series B, Jul 2, 2020, $96M — Invus [DUP], Fidelity Investments, GV, ArrowMark Partners, BlackRock, Casdin Capital, PBM Capital Group, Franklin Templeton, Perceptive Advisors, Sands Capital Alternatives, Octagon Capital Advisors, Nolan Capital, Venrock Healthcare Capital Partners
- Series A, Apr 29, 2020, $18M — PBM Capital Group, Nolan Capital

## Investors

- PBM Capital Group (https://capitalatlas.ai/funds/pbm-capital-group) — Series A, Series B
- Nolan Capital — Series A, Series B
- Invus [DUP] — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- ArrowMark Partners — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series B
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series B
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series B